Management of Invasive Candidiasis in Patients with Documented Fluconazole Allergy

First‑Line Therapy (Echinocandins)

• Echinocandins (caspofungin, micafungin, anidulafungin) are the preferred first‑line agents for invasive candidiasis or candidemia in fluconazole‑allergic patients; they have A‑I level evidence and no known azole cross‑reactivity. 1

Dosing Recommendations for Echinocandins

• Caspofungin: 70 mg loading dose, then 50 mg once daily. [1][2]
• Micafungin: 100 mg once daily. [1][2]
• Anidulafungin: 200 mg loading dose, then 100 mg once daily. [1][2]

Second‑Line Therapy (Amphotericin B Formulations)

• When echinocandins are unavailable or not tolerated, amphotericin B formulations provide an effective alternative with A‑I level evidence. [1][2]

Dosing for Amphotericin B

• Amphotericin B deoxycholate: 0.5–1.0 mg/kg per day. [1][2]3
• Lipid formulation amphotericin B (LFAmB): 3–5 mg/kg per day. [1][2]3

Species‑Specific Recommendations

Candida glabrata

• Echinocandins are strongly preferred because this species often shows reduced azole susceptibility; LFAmB is effective but less attractive. [1][2]3

Candida parapsilosis

• LFAmB (3–5 mg/kg daily) is preferred due to decreased in‑vitro activity of echinocandins; however, continuation of an echinocandin is reasonable if the patient is clinically improving and follow‑up cultures are negative. [1][2]3

Candida krusei

• Any of the following are acceptable: an echinocandin, LFAmB, or voriconazole. [4][5]

Clinical Decision Algorithm for Invasive/Systemic Infection

Safety Consideration – Avoidance of Fluconazole

• Fluconazole must not be used for de‑escalation in any patient with a documented fluconazole allergy, even when the isolate is susceptible. [1][3]

Pregnancy Considerations

• In pregnant women with fluconazole allergy, amphotericin B deoxycholate is the treatment of choice for candidemia and invasive candidiasis because it has the most established safety profile in pregnancy. [4][5]

Alternative Therapies for Fluconazole-Allergic Patients

Primary Alternatives by Clinical Scenario

• For patients with fluconazole allergy, the Infectious Diseases Society of America recommends an echinocandin (caspofungin, micafungin, or anidulafungin) as the preferred first-line alternative for invasive candidiasis and candidemia, with voriconazole or amphotericin B formulations serving as alternatives depending on the specific infection type and severity 6, 7
• Echinocandins, such as caspofungin, micafungin, and anidulafungin, are effective alternatives with A-I level evidence, providing strong efficacy and avoiding cross-reactivity concerns with azole-allergic patients 6, 7
• The recommended dosing for caspofungin is a loading dose of 70 mg, then 50 mg daily, for micafungin is 100 mg daily, and for anidulafungin is a loading dose of 200 mg, then 100 mg daily 6, 7

Species-Specific Considerations

• For Candida glabrata, the Infectious Diseases Society of America strongly prefers echinocandins over all alternatives, with lipid formulation amphotericin B (LFAmB) being less attractive 6, 8, 7
• For Candida parapsilosis, LFAmB (3-5 mg/kg daily) is preferred due to decreased in vitro activity of echinocandins against this species 8, 9, 10
• For Candida krusei, echinocandin, LFAmB, or voriconazole are all acceptable options 8, 9

Common Pitfalls to Avoid

• Topical agents, such as amphotericin B lozenges or nystatin, should not be used for mucosal candidiasis due to suboptimal efficacy and tolerability 11
• Ketoconazole should be avoided due to significant hepatotoxicity and drug interactions 11

Practical Algorithm

• For invasive or systemic infections, the Infectious Diseases Society of America recommends starting with an echinocandin (any of the three options) 6, 7
• If an echinocandin is unavailable or intolerant, LFAmB 3-5 mg/kg daily can be used 6, 7
• For step-down oral therapy needs, voriconazole can be considered only if the allergy was mild and not a true hypersensitivity reaction 6, 7